Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2004 3
2005 2
2013 1
2014 5
2015 3
2016 11
2017 13
2018 8
2019 8
2020 4
2021 3
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic Potential of Targeting PAK Signaling.
Senapedis W, Crochiere M, Baloglu E, Landesman Y. Senapedis W, et al. Among authors: baloglu e. Anticancer Agents Med Chem. 2016;16(1):75-88. doi: 10.2174/1871520615666150617111414. Anticancer Agents Med Chem. 2016. PMID: 26081410 Review.
Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers.
Khan HY, Nagasaka M, Aboukameel A, Alkhalili O, Uddin MH, Bannoura SF, Mzannar Y, Azar I, Beal EW, Tobon ME, Kim SH, Beydoun R, Baloglu E, Senapedis W, El-Rayes BF, Philip PA, Mohammad RM, Shields AF, Al Hallak MN, Azmi AS. Khan HY, et al. Among authors: baloglu e. Mol Cancer Ther. 2023 Dec 1;22(12):1422-1433. doi: 10.1158/1535-7163.MCT-23-0251. Mol Cancer Ther. 2023. PMID: 37703579 Free PMC article.
Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers.
Khan HY, Nagasaka M, Aboukameel A, Alkhalili O, Uddin MH, Bannoura S, Mzannar Y, Azar I, Beal E, Tobon M, Kim S, Beydoun R, Baloglu E, Senapedis W, El-Rayes B, Philip PA, Mohammad RM, Shields AF, Al-Hallak MN, Azmi AS. Khan HY, et al. Among authors: baloglu e. bioRxiv [Preprint]. 2023 Mar 27:2023.03.27.534309. doi: 10.1101/2023.03.27.534309. bioRxiv. 2023. PMID: 37034616 Free PMC article. Updated. Preprint.
PAK4 inhibition improves PD-1 blockade immunotherapy.
Abril-Rodriguez G, Torrejon DY, Liu W, Zaretsky JM, Nowicki TS, Tsoi J, Puig-Saus C, Baselga-Carretero I, Medina E, Quist MJ, Garcia AJ, Senapedis W, Baloglu E, Kalbasi A, Cheung-Lau G, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Wang CY, Grasso CS, Ribas A. Abril-Rodriguez G, et al. Among authors: baloglu e. Nat Cancer. 2020;1(1):46-58. doi: 10.1038/s43018-019-0003-0. Epub 2019 Dec 9. Nat Cancer. 2020. PMID: 34368780 Free PMC article.
Clinical translation of nuclear export inhibitors in cancer.
Senapedis WT, Baloglu E, Landesman Y. Senapedis WT, et al. Among authors: baloglu e. Semin Cancer Biol. 2014 Aug;27:74-86. doi: 10.1016/j.semcancer.2014.04.005. Epub 2014 Apr 19. Semin Cancer Biol. 2014. PMID: 24755012 Review.
Nucleo-cytoplasmic transport as a therapeutic target of cancer.
Gravina GL, Senapedis W, McCauley D, Baloglu E, Shacham S, Festuccia C. Gravina GL, et al. Among authors: baloglu e. J Hematol Oncol. 2014 Dec 5;7:85. doi: 10.1186/s13045-014-0085-1. J Hematol Oncol. 2014. PMID: 25476752 Free PMC article. Review.
Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.
Yan D, Pomicter AD, Tantravahi S, Mason CC, Senina AV, Ahmann JM, Wang Q, Than H, Patel AB, Heaton WL, Eiring AM, Clair PM, Gantz KC, Redwine HM, Swierczek SI, Halverson BJ, Baloglu E, Shacham S, Khorashad JS, Kelley TW, Salama ME, Miles RR, Boucher KM, Prchal JT, O'Hare T, Deininger MW. Yan D, et al. Among authors: baloglu e. Clin Cancer Res. 2019 Apr 1;25(7):2323-2335. doi: 10.1158/1078-0432.CCR-18-0959. Epub 2018 Dec 18. Clin Cancer Res. 2019. PMID: 30563936 Free PMC article.
PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus.
Mpilla GB, Uddin MH, Al-Hallak MN, Aboukameel A, Li Y, Kim SH, Beydoun R, Dyson G, Baloglu E, Senapedis WT, Landesman Y, Wagner KU, Viola NT, El-Rayes BF, Philip PA, Mohammad RM, Azmi AS. Mpilla GB, et al. Among authors: baloglu e. Mol Cancer Ther. 2021 Oct;20(10):1836-1845. doi: 10.1158/1535-7163.MCT-20-1105. Epub 2021 Jul 12. Mol Cancer Ther. 2021. PMID: 34253597 Free PMC article.
Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer.
Sexton R, Mahdi Z, Chaudhury R, Beydoun R, Aboukameel A, Khan HY, Baloglu E, Senapedis W, Landesman Y, Tesfaye A, Kim S, Philip PA, Azmi AS. Sexton R, et al. Among authors: baloglu e. Int J Mol Sci. 2019 Sep 28;20(19):4826. doi: 10.3390/ijms20194826. Int J Mol Sci. 2019. PMID: 31569391 Free PMC article.
61 results